Xenoport, Inc. operates in the Pharmaceutical preparations sector. XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates, which utilizes the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The product candidates referred to as Transported Prodrugs are created by modifying the chemical structure of marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. The product candidate, XP13512 (gabapentin enacarbil), is licensed to Astellas Pharma Inc. in Japan and five Asian countries and to Glaxo Group Limited (GSK), in the United States and all other regions globally. Horizant has completed the Phase II clinical trials for management of post-herpetic neuralgia (PHN) in the United States, and is being evaluated as a prophylactic therapy for migraine headaches in a Phase II b clinical trial. In our complete report available for purchase the company is compared to: Allos Therapeutics, Inc., Pernix Therapeutics Holdings Incorporated and Vanda Pharmaceuticals Inc..